BLU9931 CAS No.:1538604-68-0

Introduction:

BLU9931 CAS No.:1538604-68-0 is a breakthrough product in the pharmaceutical industry, known for its unique properties that make it one of the most potent inhibitors of HIF-2α. The compound is also known to be highly selective, making it an effective drug candidate for the treatment of various types of anemia in patients with chronic kidney disease. Its potency and selectivity make it the perfect drug candidate for treating a variety of diseases and conditions.

Overview:

BLU9931 CAS No.:1538604-68-0 is a small molecule inhibitor of HIF-2α, which is a member of the hypoxia-inducible factor family of transcription factors. HIF-2α plays a critical role in oxygen homeostasis and is essential for maintaining the integrity of the vascular system. Therefore, it is a potential target for the treatment of a variety of diseases, including anemia associated with chronic kidney disease (CKD).

Features and Benefits:

BLU9931 CAS No.:1538604-68-0 has several features and benefits, which make it a promising drug candidate for the treatment of anemia in CKD patients. The following are some of the significant features and benefits of the product:

Potent:

BLU9931 is a highly potent inhibitor of HIF-2α, making it an effective drug candidate for the treatment of various types of anemia in patients with chronic kidney disease. Its potency is due to its unique structure, which allows it to bind to the HIF-2α active site with high affinity and selectivity, resulting in maximal inhibition of HIF-2α activity.

Selective:

BLU9931 is highly selective, making it an excellent drug candidate for the treatment of anemia in CKD patients. Its selectivity is due to its ability to specifically target the HIF-2α active site, leaving other cellular mechanisms untouched. This property also reduces the risk of off-target side effects, making it a safe and effective drug candidate.

Non-toxic:

BLU9931 is a non-toxic small molecule inhibitor of HIF-2α, making it a safe drug candidate for the treatment of anemia in CKD patients. Its non-toxicity is due to its unique structure, which ensures that it does not interfere with other essential cellular processes, resulting in negligible toxicity.

Applications:

BLU9931 CAS No.:1538604-68-0 has broad applications in the pharmaceutical industry, mainly in the treatment of anemia in CKD patients. The following are some of the significant applications of the product:

Treatment of Anemia in CKD Patients:

BLU9931 is an effective drug candidate for the treatment of anemia in CKD patients. Anemia is a prevalent condition in CKD patients that results from a deficiency in erythropoietin, a hormone produced by the kidneys. BLU9931 works by inhibiting HIF-2α, which promotes the production of erythropoietin, resulting in an increase in red blood cell production, and thus, reducing anemia.

Conclusion:

BLU9931 CAS No.:1538604-68-0 is an innovative product that has the potential to revolutionize the pharmaceutical industry. Its unique features, benefits, and applications make it a promising drug candidate for the treatment of anemia in CKD patients. Its potency, selectivity, and non-toxicity make it a safe and effective drug candidate for the treatment of severe diseases. As a manufacturer, we are committed to providing high-quality products to our customers, and BLU9931 is no exception. It's our pleasure to offer this innovative product to our valued customers, and we look forward to working with you to improve the health of patients worldwide.

Chemical Structure : BLU9931

CAS No.: 1538604-68-0

 

BLU9931 (BLU-9931)

Catalog No.: URK-V694 Only Used For Lab.

BLU9931 (BLU-9931) is a potent, selective, irreversible inhibitor of FGFR4 with IC50 of 3 nM, shows much weaker activity for FGFR1 (IC50=591 nM), FGFR2 (IC50=493 nM) and FGFR3 (IC50=150 nM).

Biological Activity

BLU9931 (BLU-9931) is a potent, selective, irreversible inhibitor of FGFR4 with IC50 of 3 nM.
BLU9931 shows much weaker activity for FGFR1 (IC50=591 nM), FGFR2 (IC50=493 nM) and FGFR3 (IC50=150 nM).
BLU9931 potently and selectively inhibits FGFR4 signaling and cell proliferation in HCC cell lines with an activated FGFR4 signaling pathway (Huh-7 cell IC50=110 nM, JHH-7 IC50=20 nM).
BLU9931 shows remarkable antitumor activity in mice bearing HCC tumor xenograft that overexpresses FGF19.

Physicochemical Properties

References

1. Hagel M, et al. Cancer Discov. 2015 Apr;5(4):424-37.

2. Packer LM, et al. Cancer Discov. 2015 Apr;5(4):355-7.

3. Yamamoto M, et al. Cancer Sci. 2018 Mar 13. doi: 10.1111/cas.13569.

URK-V694_COA

URK-V694_SDS

URK-V694_TDS

 

Note: All products of Ureiko are only used for scientific research or drug certificate declaration, and we do not provide products and services for any personal use!

Why choose us?

• Our team of experts is dedicated to providing the best possible service to our customers.
• We are a leading company engaged in the development and manufacture of BLU9931 CAS No.:1538604-68-0, our products are sold all over the world and are well received by customers.
• We pride ourselves on offering the highest quality Tyrosine Kinase Library products at affordable prices.
• The company has built a comprehensive network of scientists and continues to recruit top talents worldwide.
• Our pricing structure is transparent and straightforward, with no hidden fees or charges for our Tyrosine Kinase Library products.
• We always believe that team is the cornerstone of enterprise development, and only by gathering collective wisdom can we continue to innovate and shine.
• Our Tyrosine Kinase Library products are widely used in research and development, pharmaceuticals, and other industries.
• Our company is constantly introducing new BLU9931 CAS No.:1538604-68-0 in the hope of attracting more customers.
• Our Tyrosine Kinase Library products are designed to provide consistent performance, batch after batch.
• We strive to create more advanced enterprise core competitiveness.

Hot Tags: blu9931 cas no.:1538604-68-0, China blu9931 cas no.:1538604-68-0, epigenetic library for epigenetic analysis of epigenetic genotype, epigenetic library for epigenetic regulation of cell differentiation, agonists for skin grafting, epigenetic library for epigenetic regulation of cell proliferation, inhibitors for pathogen recognition, epigenetic library for epigenetic analysis of epigenetic editing